Overview
- Revenue rose to $1.21 billion, roughly 22% higher year over year, with adjusted earnings of $0.61 per share beating consensus.
- The company raised full‑year revenue guidance to $4.63 billion to $4.65 billion but cut its non‑GAAP gross‑margin outlook to 61% due to third‑party component issues increasing material discard.
- Shares fell more than 8% after hours following the report and were down around 17% by late Friday morning as investors reacted to margins and management’s 2026 growth commentary.
- Growth initiatives included broader G7 access such as Ontario Drug Benefit coverage, an AI‑powered meal logging feature in G7 and Stelo apps, and Stelo topping $100 million in first‑year sales.
- Dexcom submitted its Smart Basal insulin‑dosing tool to the FDA and highlighted leadership changes with interim CEO Jake Leach, while a class‑action lawsuit related to G7 remains active.